Albuminuria in Type 2 Diabetes and Risk of Cardiorenal Outcomes
Authors' conclusion
The prevalence of patients with T2D and albuminuria was 40% and may benefit from cardiovascular and renoprotective drugs, whereas 60% with normoalbuminuria still have a high residual risk of cardiovascular disease, warranting increased focus.
Study context
- Population
- Adults (≥18 years) with T2DM at index January 1, 2015, with urinary albumin-to-creatinine ratio (UACR) and creatinine measured within 365 days prior
- Participants
- 74,014 adults
- Exposure
- Albuminuria vs normoalbuminuria
- Albuminurian = 29,581
- Outcome
- Composite of:
- HF
- MI
- Stroke
- All-cause death
- Follow-up
- 4 years
Methodological detailsDanish nationwide registers
- Danish nationwide registers
Main finding
As reported in the abstract
Absolute 4-year risk of HF, MI, stroke or all-cause death
Observational data: associations, not effects.
Secondary outcomes
Baseline characteristics
Duration of diabetes Albuminuria 8.2 years · Normoalbuminuria 6.9 years
eGFR Albuminuria 76 · Normoalbuminuria 83
Males
| Outcome | Albuminuria | Normoalbuminuria |
|---|---|---|
| Absolute 4-year risk of end-stage renal disease or sustained eGFR decrease ≥50% | 8.7% (95% CI 8.4%–9.0%) | 2.9% (95% CI 2.8%–3.1%) |
- Prevalence of albuminuria
- 40% · 29,581
Original publication
Albuminuria in Type 2 Diabetes and Risk of Cardiorenal Outcomes. JACC Adv. Published 23 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →